Skip to main content

Table 1 Demographic information

From: Evaluation of the tracing effect of carbon nanoparticle and carbon nanoparticle-epirubicin suspension in axillary lymph node dissection for breast cancer treatment

Clinical pathological feature Control (n = 30) Tracer (n = 30) Drug-load (n = 30) Test value P
Average age (year) 45.4 ± 7.8 47.1 ± 8.3 48.4 ± 9.8 0.885* 0.416
Tumor location     10.258# 0.247
 Upper outer quadrant 18 21 26   
 Lower outer quadrant 5 3 0   
 Upper inner quadrant 3 4 3   
 Lower inner quadrant 1 0 1   
 Central area 3 2 0   
Clinical stage     2.018# 0.732
 I 8 8 6   
 II 18 15 16   
 IIIA 4 7 8   
Pathological type     3.000# 0.558
 Infiltrating ductal carcinoma 29 29 29   
 Mucinous carcinoma 1 1 0   
 Medullary carcinoma 0 0 1   
ER     1.348# 0.510
 Positive 19 20 23   
 Negative 11 10 7   
PR     0.098# 0.952
 Positive 20 19 20   
 Negative 10 11 10   
HER-2     4.229# 0.121
 Positive** 3 8 3   
 Negative## 27 22 27   
Surgical approach     4.488# 0.344
 Modified radical mastectomy 20 25 18   
 Endoscopic subcutaneous mammary resection + axillary lymph nodes dissection + reconstruction with implants 9 4 11   
 Breast-conserving surgery + axillary lymph nodes dissection 1 1 1   
  1. ER estrogen receptor, PR progesterone receptor, HER-2 human epidermal growth factor receptor 2, IHC immunohistochemistry
  2. *F value; #χ 2 value; **IHC (3+) in the first biopsy before surgery; ##IHC (0 ~ 2+) in the first biopsy before surgery